一般人群中血管生物标志物的预后价值
该研究为基于28个人群队列的个体水平分析,纳入12个国家、4大洲的164054名个体(中位年龄53.1岁,女性52.4%),中位随访11.8年。检测高敏肌钙蛋白I、高敏肌钙蛋白T、N末端B型利钠肽原、B型利钠肽或高敏C反应蛋白,主要终点为致死和非致死性动脉粥样硬化性心血管病事件。所有生物标志物均与主要终点及所有次要终点显著相关(每1-SD变化的亚分布HR 1.13-1.21);单个标志物加入已确立危险因素模型可改善C统计量,在<65岁人群中高敏肌钙蛋白I、N末端B型利钠肽原和高敏C反应蛋白联合使10年动脉粥样硬化性心血管病C统计量从0.812提高至0.8194,并改善重分类;对心力衰竭和全因死亡的预测改善最明显,≥65岁人群的增量价值大于年轻人群。
要点
- 在164054名一般人群中,所有检测的生物标志物均与动脉粥样硬化性心血管病事件显著相关:高敏肌钙蛋白I每1-SD变化亚分布HR 1.13(95%CI 1.11-1.16),高敏肌钙蛋白T 1.18(95%CI 1.12-1.23),N末端B型利钠肽原1.21(95%CI 1.18-1.24),B型利钠肽1.14(95%CI 1.08-1.22),高敏C反应蛋白1.14(95%CI 1.12-1.1
- 在<65岁人群中,高敏肌钙蛋白I、N末端B型利钠肽原和高敏C反应蛋白联合使10年动脉粥样硬化性心血管病C统计量从0.812(95%CI 0.8021-0.8208)提高至0.8194(95%CI 0.8089-0.8277),并较传统模型改善重分类。
- 生物标志物对心力衰竭和全因死亡的预测改善最明显,且≥65岁人群的增量价值大于<65岁人群。
- 所有生物标志物均与所有次要终点(全因死亡、心力衰竭、缺血性卒中、心肌梗死)显著相关。
适用人群与场景
- 来自12个国家、4大洲的28个人群队列的164054名个体,中位年龄53.1岁(IQR 42.7-62.9岁),女性占52.4%。
- 一般人群场景,用于评估动脉粥样硬化性心血管病的一级预防风险分层。
研究设计与关键结果
- 研究类型:基于28个人群队列的个体水平分析,中位随访11.8年,纳入164054名个体,发生17211例动脉粥样硬化性心血管病事件。
- 所有生物标志物均与动脉粥样硬化性心血管病事件显著相关:高敏肌钙蛋白I每1-SD变化亚分布HR 1.13(95%CI 1.11-1.16),高敏肌钙蛋白T 1.18(95%CI 1.12-1.23),N末端B型利钠肽原1.21(95%CI 1.18-1.24),B型利钠肽1.14(95%CI 1.08-1.22),高敏C反应蛋白1.14(95%CI 1.12-1.16)。
- 所有生物标志物均与所有次要终点(全因死亡、心力衰竭、缺血性卒中、心肌梗死)显著相关。
- 单个生物标志物加入已确立危险因素模型均改善C统计量;在<65岁人群中,高敏肌钙蛋白I、N末端B型利钠肽原和高敏C反应蛋白联合使10年动脉粥样硬化性心血管病C统计量从0.812(95%CI 0.8021-0.8208)提高至0.8194(95%CI 0.8089-0.8277),并较传统模型改善重分类。
- 风险预测改善对心力衰竭和全因死亡最明显;生物标志物的增量价值在≥65岁人群大于<65岁人群。
证据类型、等级与局限
- 证据类型:基于28个人群队列的个体水平分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在一般人群中,将高敏肌钙蛋白I、N末端B型利钠肽原和高敏C反应蛋白等生物标志物加入已确立危险因素,对动脉粥样硬化性心血管病风险预测仅小幅改善(<65岁人群C统计量从0.812提高至0.8194),对心力衰竭和全因死亡的预测改善更明显。
- 生物标志物的增量预测价值在≥65岁人群大于<65岁人群。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Identification of individuals at high risk for atherosclerotic cardiovascular disease within the population is important to inform primary prevention strategies.
OBJECTIVE: To evaluate the prognostic value of routinely available cardiovascular biomarkers when added to established risk factors.
DESIGN, SETTING, AND PARTICIPANTS: Individual-level analysis including data on cardiovascular biomarkers from 28 general population-based cohorts from 12 countries and 4 continents with assessments by participant age. The median follow-up was 11.8 years.
EXPOSURE: Measurement of high-sensitivity cardiac troponin I, high-sensitivity cardiac troponin T, N-terminal pro-B-type natriuretic peptide, B-type natriuretic peptide, or high-sensitivity C-reactive protein.
MAIN OUTCOMES AND MEASURES: The primary outcome was incident atherosclerotic cardiovascular disease, which included all fatal and nonfatal events. The secondary outcomes were all-cause mortality, heart failure, ischemic stroke, and myocardial infarction. Subdistribution hazard ratios (HRs) for the association of biomarkers and outcomes were calculated after adjustment for established risk factors. The additional predictive value of the biomarkers was assessed using the C statistic and reclassification analyses.
RESULTS: The analyses included 164 054 individuals (median age, 53.1 years [IQR, 42.7-62.9 years] and 52.4% were women). There were 17 211 incident atherosclerotic cardiovascular disease events. All biomarkers were significantly associated with incident atherosclerotic cardiovascular disease (subdistribution HR per 1-SD change, 1.13 [95% CI, 1.11-1.16] for high-sensitivity cardiac troponin I; 1.18 [95% CI, 1.12-1.23] for high-sensitivity cardiac troponin T; 1.21 [95% CI, 1.18-1.24] for N-terminal pro-B-type natriuretic peptide; 1.14 [95% CI, 1.08-1.22] for B-type natriuretic peptide; and 1.14 [95% CI, 1.12-1.16] for high-sensitivity C-reactive protein) and all secondary outcomes. The addition of each single biomarker to a model that included established risk factors improved the C statistic. For 10-year incident atherosclerotic cardiovascular disease in younger people (aged <65 years), the combination of high-sensitivity cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and high-sensitivity C-reactive protein resulted in a C statistic improvement from 0.812 (95% CI, 0.8021-0.8208) to 0.8194 (95% CI, 0.8089-0.8277). The combination of these biomarkers also improved reclassification compared with the conventional model. Improvements in risk prediction were most pronounced for the secondary outcomes of heart failure and all-cause mortality. The incremental value of biomarkers was greater in people aged 65 years or older vs younger people.
CONCLUSIONS AND RELEVANCE: Cardiovascular biomarkers were strongly associated with fatal and nonfatal cardiovascular events and mortality. The addition of biomarkers to established risk factors led to only a small improvement in risk prediction metrics for atherosclerotic cardiovascular disease, but was more favorable for heart failure and mortality.
参考来源
- Neumann JT, Twerenbold R, Weimann J, et al. Prognostic Value of Cardiovascular Biomarkers in the Population. JAMA. 2024. PMID: 38739396. doi:10.1001/jama.2024.5596
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。